A salivary proteome biomarker for depression

Abstract

The invention discloses a salivary proteome depression biomarker, which comprises Cystatin-C, Ig alpha-1 chain C region, Cystatin-S, Lysozyme C, Cystatin-D, Protein LEG1homolog, Prolactin-inducible protein, Nucleobindin-2, Phosphoglycerate kinase 1, Carbonic anhydrase 6, Glyceraldehyde‑3‑phosphate dehydrogenase, Annexin A3, Apolipoprotein A‑I, Profilin‑1, Peroxiredoxin‑5, Aspartate aminotransferase, Vinculin, Calpain‑1catalytic subunit, Keratin, type II cytoskeletal 78, Lamin‑ B1, Plastin‑2, Neutrophil gelatinase‑associated lipocalin, Periplakin, Protein‑glutamine gamma‑glutamyltransferase E, Calmodulin, Alpha‑2‑macroglobulin‑likeprotein 1, Protein S100‑A8, Protein S100‑A9, Protein S100‑P, Keratin, At least three of type II cytoskeletal 5, Protein S100‑A7, Keratin and type I cytoskeletal13. The saliva proteome provided by the present invention is a simple and non-invasive biomarker for depression, and the specificity and sensitivity to depression can reach more than 80%. The kit can quickly and effectively detect and predict depression, so as to prevent and delay depression.

Description

technical field [0001] The invention relates to the technical field of biomarkers, in particular to a salivary proteome depression biomarker. Background technique [0002] Depression refers to a mood and affective disorder caused by multiple factors such as mood disorders and genetic factors, with significant and persistent low mood, slow thinking, cognitive impairment, decreased volitional activity and somatic symptoms as the main clinical features. . Depression has a wide range of onset, it is not easy to detect in the early stage, and there are individual differences in the efficacy of antidepressants. Therefore, the accurate diagnosis and efficacy evaluation of depression are not only the key issues that need to be solved clinically, but also for understanding the substance and pathology of the disease. Foundations also play an important role. [0003] Since there is no biomarker that can become the gold standard for clinical research, genetics, clinical manifestations...

AI Technical Summary

Problems solved by technology

[0003] Since there is no biomarker that can become the gold standard for clinical research, genetics, clinical manifestations (inquiry) and neurobiological indicators are the main methods for diagnosing depression, but the evaluation of clinical symptoms is not stable enough for diagnosis. The conditions for genetic factors to play a role are not clear enough. In contrast, the information provided by neurobiological indicators is more accurate and detailed, and the development prospects are broader

Images